Latest Innovation News

Axel REE Limited reports a remarkable 145% increase in rare earth elements and 339% gallium resource growth at its Caladão Project, alongside a metallurgical breakthrough that could slash development costs through in-situ leaching.

Eden Innovations has significantly reduced its debt burden and secured fresh capital, while expanding sales and trials of its advanced concrete additives across key international markets.

Epiminder Limited has successfully listed on the ASX, raising $125 million to commercialise its FDA-approved Minder device. The company has initiated the first US implant and secured five leading medical centres for its DETECT study.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

Australian Mines Limited reports strong gold drilling results at its Boa Vista project in Brazil and initiates new scandium-nickel-cobalt drilling in NSW, supported by a $4 million capital raise to accelerate exploration.

Strategic Elements Ltd reports steady progress in its cutting-edge ventures across automation, AI, and material science, supported by a strong cash position and government-backed innovation incentives.

Argenica Therapeutics has unveiled compelling AI-driven results confirming ARG-007’s significant benefits in severe acute ischemic stroke patients, setting the stage for a precision-focused Phase 2b trial.

Talga Group has successfully raised A$7.3 million through an oversubscribed Share Purchase Plan, surpassing its A$5 million target to fund a significant ramp-up in graphite anode production and support strategic growth initiatives.